Celularity Inc. — Cyborg Score 4/10

Strategic Profile

The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Recently, Celularity completed a significant balance sheet restructuring by retiring $41.6 million in senior secured debt while maintaining exclusive licensing rights to its intellectual property for 5 years.

Cyborg Score Rationale

Celularity demonstrates strong revenue growth (138% YoY in 2024) and operational improvements, but faces structural challenges including micro-cap status (~$45M market cap), prior Nasdaq compliance issues, and significant operating losses despite revenue growth. Recent debt restructuring and licensing deals show management adaptation.

Top Insights

• 2024 revenue grew 138% to $54.2 million from $22.8 million in 2023
• Successfully eliminated $41.6 million in senior secured debt through strategic IP asset sale in 2025
• Key pipeline includes PDA-001 for Crohn's disease, PDA-002 for muscular dystrophy, and pExo-001 exosome therapy for osteoarthritis
• Regained Nasdaq listing compliance in 2025 following filing of delinquent quarterly reports

Named Competitors

• Allogeneic Cell Therapy — Clinical-stage competitors developing alternative allogeneic cell therapies
• CAR-T and NK Cell Therapies — Established players in engineered cell therapy development
• Surgical Biomaterials — Competitors in advanced wound care and surgical biomaterial markets

Recent Developments

• (February 2026) Received $12.2M from sale of New Jersey net operating losses
• (December 2025) Secured additional financing and announced strategic shift in capital allocation
• (November 2025) Resolved Nasdaq listing compliance matter after addressing delayed filings

Open the full interactive Celularity Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.